Sentinel Trust Co. LBA Purchases New Position in Nautilus Biotechnology, Inc. $NAUT

Key Points

• Sentinel Trust Co. LBA opened a new position of 750,000 shares in Nautilus Biotechnology during Q4, a stake valued at about $1.46 million and representing 0.59% ownership.
• CEO Sujal M. Patel purchased 25,000 shares at roughly $2.61 on March 4, boosting his holdings to 10,366,721 shares, and insiders now own 41.1% of the company.
• Analyst views are mixed with a consensus rating of "Hold" and a $4.00 price target; Guggenheim upgraded to a Buy and raised its target to $4 while Weiss Ratings reiterated a Sell (D-).

Sentinel Trust Co. LBA purchased a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 750,000 shares of the company's stock, valued at approximately $1,462,000. Sentinel Trust Co. LBA owned 0.59% of Nautilus Biotechnology at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of NAUT. Bank of America Corp DE grew its stake in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock worth $83,000 after purchasing an additional 13,363 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Nautilus Biotechnology by 29.5% in the 3rd quarter. Squarepoint Ops LLC now owns 131,827 shares of the company's stock valued at $111,000 after purchasing an additional 30,005 shares during the period. XTX Topco Ltd lifted its stake in shares of Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company's stock valued at $48,000 after purchasing an additional 30,641 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in Nautilus Biotechnology during the third quarter valued at $38,000. Finally, Jacobs Levy Equity Management Inc. grew its position in Nautilus Biotechnology by 18.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 301,012 shares of the company's stock valued at $254,000 after buying an additional 46,153 shares during the period. Hedge funds and other institutional investors own 50.71% of the company's stock.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel purchased 25,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were purchased at an average cost of $2.61 per share, with a total value of $65,250.00. Following the purchase, the chief executive officer owned 10,366,721 shares of the company's stock, valued at $27,057,141.81. This represents a 0.24% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 41.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nautilus Biotechnology in a research report on Tuesday, April 21st. Guggenheim raised their target price on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a "buy" rating in a research report on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Nautilus Biotechnology has a consensus rating of "Hold" and a consensus price target of $4.00.

Nautilus Biotechnology Stock Performance

Shares of NASDAQ NAUT opened at $2.62 on Monday. The firm has a market cap of $331.59 million, a PE ratio of -5.57 and a beta of 1.08. The firm has a fifty day moving average of $2.90 and a 200 day moving average of $2.22. Nautilus Biotechnology, Inc. has a one year low of $0.62 and a one year high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.

Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.